SV

Street Verdict

Analyst Scorecard

A record of what Nikhil Ranka said publicly, with the source. Not advice.

Pending — not yet graded
“Bearish on the Pharma sector, expecting a very challenging FY26. The sector's recent result season was subdued, and there's no clear visibility on new drugs to fill the significant void created by Revlimid going off patent in January 2026, which was a major earnings contributor.”
Nifty PharmaBearishCalled 30 May 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Nikhil Ranka’s full track record